Invention Grant
- Patent Title: Regimen for suppressing organ rejection
-
Application No.: US17447581Application Date: 2021-09-14
-
Publication No.: US11957666B2Publication Date: 2024-04-16
- Inventor: William J. Polvino
- Applicant: Veloxis Pharmaceuticals, Inc.
- Applicant Address: US NC Cary
- Assignee: VELOXIS PHARMACEUTICALS, INC.
- Current Assignee: VELOXIS PHARMACEUTICALS, INC.
- Current Assignee Address: US NC Cary
- Agency: Blank Rome LLP
- Main IPC: A61K31/435
- IPC: A61K31/435 ; A61K9/00 ; A61K9/20 ; A61K31/436 ; A61K31/5377 ; A61K39/395 ; A61K45/06 ; A61P43/00 ; A61K39/00

Abstract:
The present invention relates to a method of suppressing organ rejection in a patient receiving an organ transplant by initiating oral treatment with a once-daily extended release tacrolimus dosage form, for example, at an initial dose of from about 0.15 to about 0.20 mg/kg/day within 24 or 48 hours following transplantation. The once-daily extended release tacrolimus dosage form (i) provides low fluctuation and/or swing of tacrolimus, (ii) provides a significantly lower Cmax than an immediate release formulation of tacrolimus while providing the same or greater area under the curve (AUC), (iii) releases the tacrolimus substantially in the colon and/or the lower ileum, (iv) releases at most 63.5% of the tacrolimus in the dosage form at the 12 hour time point, or (v) any combination of any of the foregoing.
Public/Granted literature
- US20220249449A1 REGIMEN FOR SUPPRESSING ORGAN REJECTION Public/Granted day:2022-08-11
Information query